Advertisement

Topics

Latest "Lilly Holds Press Conference Detail Leadership Changes" News Stories

20:11 EDT 25th March 2019 | BioPortfolio

Here are the most relevant search results for "Lilly Holds Press Conference Detail Leadership Changes" found in our extensive news archives from over 250 global news sources.

More Information about Lilly Holds Press Conference Detail Leadership Changes on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Lilly Holds Press Conference Detail Leadership Changes for you to read. Along with our medical data and news we also list Lilly Holds Press Conference Detail Leadership Changes Clinical Trials, which are updated daily. BioPortfolio also has a large database of Lilly Holds Press Conference Detail Leadership Changes Companies for you to search.

Showing "Lilly Holds Press Conference Detail Leadership Changes" News Articles 1–25 of 12,000+

Monday 25th March 2019

At AIPAC Policy Conference, Israel’s Sheba Medical Center Recognized as Global Leaders in Healthcare Innovation

Israel’s Sheba Medical Center and Dr. Nathalie Bloch were recognized on Sunday at AIPAC’s annual policy conference in Washington, DC. for bringing pioneering medical advancements to the Middle East and the World. On the heels of Sheba Medical Center being named one of “The Top 10 Hospitals in the World,” Dr. Bloch spoke about Israel’s role as a medical powerhouse across the globe. WASHIN...


bluebird bio Statement on European Regulatory Status of LentiGlobin™

A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as p...

Widex USA to Showcase Its Latest Technology at AAA Booth #1025 – March 27-29, 2019

Visitors to Demo Widex ENERGY CELL™ Technology and Get a Live Hearing Demo of Second Generation Widex EVOKE™ Widex USA, Inc. will be exhibiting at the 20


Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to...

Veracyte Announces New Afirma Xpression Atlas Data that Advance Genomic Understanding of Medullary Thyroid Cancer

Findings Presented at ENDO 2019 Conference Veracyte, Inc. (Nasdaq: VCYT) announced today that new data from the Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC) are associated with variants from three genes. The findings shed new light on the genomic underpinning of this rare, but aggressive, ...

Oragenics Announces Closing of $12.5 Million Underwritten Public Offering

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced the closing of its previously announced underwritten public offering of 16,666,668 shares of common stock, short-term warrants to purchase up to 8,333,334 shares of common stock, and ...

Arizona Technology Council Urges Support for Senate Bill 1085, Enabling Affordable Health Coverage for Small Businesses

SB1085 Creates a New Pathway for Association Health Plans, Allowing Small Employers to Band Together to Purchase Coverage Options Currently Only Available to Large Employers In order to give small businesses better access to health coverage, the Arizona Technology Council urges the business community to support Arizona

Proteostasis Puts Best Face On Unspectacular CF Combo Data

With data showing a lung function and sweat chloride benefit for its proprietary CFTR-modulating triplet, Proteostasis says it’s moving ahead...   

Signs Of Change? Lilly, Merck, Janssen Report Slowing List Price Growth In 2018

Annual transparency reports from the three firms show US price increases continued, though less aggressively, and net prices declined for...   

NantHealth to Report 2018 Fourth-Quarter Financial Results and Host Conference Call on Thursday, March 28

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2018 fourth quarter on Thursday, March 28, 2019, after market close. NantHealth management will host a conference call that same day at 1:30 p.m. PT (4:30 p.m. ET) to review the company’s perf...

STAT Plus: Under pressure over its pricing of insulin, Eli Lilly issued a report in which it claims that the price it was paid for a key diabetes treatment fell by 8.1 percent over the past five years. https://buff.ly/2JArLPI 

STAT Plus: Under pressure over its pricing of insulin, Eli Lilly issued a report in which it claims that the price it was paid for a key diabetes treatment fell by 8.1 percent over the past five years. https://buff.ly/2JArLPI 

New Data on Fibered vs. Non-Fibered Coil Embolization

A new animal study concludes that fewer fibered embolization coils are needed to achieve acute occlusion when compared with similar bare metal coils. The study was presented today at an industry sponsored symposium during the 2019 annual meeting of the Society of Interventional Radiology (SIR) in Austin, Texas. Embolization is a nonsurgical, minimally...

Circulatory Death Donor Hearts: Has the Time Come?

(MedPage Today) -- Australians detail experience expanding beyond brain dead donations

Biofrontera AG: Biofrontera provides corporate update; conference call details for March 26, 2019

DGAP-News: Biofrontera AG / Key word(s): Mergers & Acquisitions/Acquisition 25.03.2019 / 16:30 The issuer is solely responsible for the content of this announcement. Biofrontera provides corporate update; conference call details for March 26, 2019 Leverkusen, Germany, March 25, 2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biophar...

The International Society for Quality in Health Care Partners with the Patient Safety Movement Foundation to Achieve Zero Preventable Deaths in Hospitals

The International Society for Quality in Health Care (ISQua) is pleased to announce their support of the Patient Safety Movement Foundation (PSMF) and their mission to eliminate preventable deaths in hospitals, with a signed cooperation agreement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2019032500...

Arvinas Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of PROTAC

Arvinas (NASDAQ:ARVN) has announced the dosing of its first patient in its Phase 1 clinical trial of ARV-110, its oral androgen receptor (AR)-targeted PROTAC protein degrader. As quoted in the press release: The study will evaluate the safety, tolerability, and pharmacokinetics of ARV-110 in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on … Contin...

Daon Among First to Receive FIDO2 Certification

Global biometric identity assurance leader and FIDO Alliance Board member receives UAF 1.1 certifications concurrently Daon, a global leader in biometric identity technology, today announced certification by the FIDO Alliance for the FIDO2 protocol on server, as well as for the UAF 1.1 protocol on server and Android client SDK. FIDO2, w...

CStone appoints three distinguished oncology leaders Drs. Paul A. Bunn, Jr., Elizabeth M. Jaffee and Richard S. Finn to its Scientific Advisory Board

SHANGHAI, March 25, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) is pleased to announce the appointment of three internationally renowned oncologists Paul A. Bunn, Jr., MD, Elizabeth M. Jaffee, MD, and Richard S. Finn, MD, as the company's Scientific Advisory Board (SAB) members. With their deep scientific and medical expertise as well as extensive leadership and ad...

Biofrontera AG: Biofrontera, Inc., USA, acquires Cutanea Life Sciences, Inc., USA

Biofrontera AG / Key word(s): Mergers & Acquisitions Biofrontera AG: Biofrontera, Inc., USA, acquires Cutanea Life Sciences, Inc., USA 25-March-2019 / 15:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad-hoc...

U.S. Physical Therapy to Present at the Sidoti & Company Spring 2019 Investor Conference

U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics (the “Company”), today announced that its Chief Executive Officer, Chris Reading, will present at the Sidoti & Company Spring 2019 Investor Conference on Thursday, March 28, 2019. The presentation will cover an overview of the Company. The conferenc...

Update on Optimized Patient Blood Management (CME/CE)

(MedPage Today) -- International PBM guideline based on Frankfurt Consensus Conference covers blood-sparing approaches

Thermo Fisher to buy gene therapy contract manufacturer Brammer Bio for $1.7B

Brammer specializes in contract services for viral vector-based gene therapies. Panelists at a conference last week stressed the importance of manufacturing for gene therapy investors.

To Advance Collaboration in Precision Medicine, Bio-IT World Opens Global Event to the Public April 16-18, 2019

Through April 5, Register for Complimentary Exhibit Hall & Keynote Pass to Boston Conference & Expo In the spirit of open collaboration, the world’s premier bio-IT conference is inviting the community to experience and contribute to the future of precision medicine—together. With a focus on AI, data science and other “data-driven...

Agiliti, Inc. Announces Commencement of Cash Tender Offer for Its Warrants

Agiliti, Inc. (“Agiliti”) today announced that it has commenced a tender offer to purchase all of its outstanding warrants at a purchase price of $0.40 per warrant, in cash, without interest (the “Offer”). The purpose of the Offer is to provide the holders of the warrants who do not wish to retain their warrants, the opportunity to obtain liquidity for th...

Chemicals in Household Dust Linked to Fat Cell Development

Researchers say that endocrine-disrupting chemicals present in household dust promote the development of fat cells in a cell model and could contribute to increased growth in children relative to their age. The Duke University team will detail its findings today at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans. “This is some of […] The post Chemicals in Househo...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks